Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00202436 | Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy | PHASE3 | COMPLETED | 40 | — | — | Oct 1, 2004 | Sep 1, 2009 | Oct 20, 2009 | 1 | Netherlands |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Phlebotomy |
| 2 | ACTIVE_COMPARATOR | Erythrocytapheresis |
| Name | Type | Description |
|---|---|---|
| Phlebotomy | PROCEDURE | Removal of 500 ml whole blood |
| Erythrocytapheresis | PROCEDURE | machinal removal of erythrocytes |
Inclusion Criteria: * Hereditary haemochromatosis patients Exclusion Criteria: * Malignancies, severe arrhythmias, congestive heart failure and/or recent angina, severe liver disease, epileptic seizures preceding in last 3 months before planned treatment